出國報告（出國類別：開會）

2024 年新加坡亞太風濕病學會聯盟醫學會議心得報告

服務機關：高雄榮民總醫院兒童醫學部
姓名職稱：翁根本/科主任
派赴國家：新加坡
出國期間：2024/08/20-2024/08/26
報告日期：2024/09/10

摘要

2024 年亞太風濕病學會聯盟醫學會議於新加坡舉行，時間是 2024 年 8 月 21 日至 2024 年 8 月 25 日，本人有幸參與此會議，發表論文『川崎氏症和兒童多系統發炎症後群與新冠肺炎感染相關性』，收穫良多。上千多位來自世界各國的醫師專家來參與這個盛會，會議內容是探討各種風濕免疫疾病、血管炎和新冠肺炎相關免疫疾病問題，非常多樣豐富，且有機會和其他國家專家交流合作，個人有吸收到相當多新知，對於照顧川崎氏症病童有相當多的幫助。本人和其他各國學者有深入討論，收穫很多，這些交流經驗有助於資料整理和論文發表。參加會議的每一天，都有滿滿收穫和豐富資料，依依不捨離開新加坡，希望很快就能再和這些學者做學術經驗上的交流。

關鍵字：川崎氏症、兒童多系統發炎症後群、新冠肺炎感染

目次

一、目的

2024 年亞太風濕病學會聯盟醫學會議於新加坡舉行，時間是 2024 年 8 月 21 日至 2024 年 8 月 25 日，本人參與此會議，並發表論文『川崎氏症和兒童多系統發炎症後群與新冠肺炎感染相關性』。

二、過程

2024-8-20

由桃園搭機至新加坡。

2024-8-21

到會場報到，並參加會議，今天是超音波專題討論會。

2024-8-22

今天會議主題是紅斑性狼瘡疾病、免疫學、血管炎等題目，做深入教學和討論，其中血管炎專題討論會，對我的臨床照顧和研究幫助很大。

2024-8-23

今天會議主題是風溼性關節炎影像檢查和標靶藥物治療、紅斑性狼瘡疾病相關腎病處置、兒科風溼免疫疾病、血管炎新知、和精準檢測和資料分析等精彩演講；另一個重頭戲是發表下列論文『川崎氏症和兒童多系統發炎症後群與新冠肺炎感染相關性』，本人和其他各國學者有深入討論，收穫很多，這些交流經驗有助於資料整理和論文發表。

2024-8-24

今天會議主題是關節炎和紅斑性狼瘡疾病診斷治療新進展，以及如何將血管炎治療到最好的狀態，我的研究重心川崎氏症，就是一種血管發炎疾病，這方面的新知，對我照顧病人和做相關研究的幫助很大。

2024-8-25

今天會議主題是探討發炎性關節炎、兒科自體免疫疾病、和骨質疏鬆症等，聽完這些演講，收穫很多。

2024-8-26

由新加坡搭機回國。

三、心得及建議

本人參加這次會議，和其他各國學者有深入討論，收穫很多，這些交流經驗有助於資料整理和論文發表。參加會議的每一天，都有滿滿收穫和豐富資料，依依不捨離開新加坡，希望很快就能再和這些學者做學術經驗上的交流。建議大家可以整理自己研究心得，積極參與國際醫學會議，增廣自己見聞，院方也能給予適當獎勵補助。

附錄



Program at a Glance

APLAR24 Program

Thursday 22 August 2024

Timings subject to Workshop	Room 331 - 332	Room 324	Room 325	Summit 2	Room 335 - 336
	MSK Ultrasound Workshop Day 2 0700 - 0915 The MSK Ultrasound Workshop is endorsed by the Chapter of Rheumatologists, College of Physicians, Singapore. SPONSORED BY Canon		Lupus workshop co-organised by Lupus Academy 0900 - 1020	GRAPPA Workshop 0900 - 1000 SPONSORED BY NOVARTIS	Systemic Sclerosis Workshop 0830 - 1010 SPONSORED BY
	Break			Break	
	MSK Ultrasound Workshop Day 2 cont. 0900 - 1230	Immunology Workshop 1030 - 1215	Lupus workshop co-organised by Lupus Academy cont. 1040 - 1240	GRAPPA Workshop cont. 1020 - 1200	Systemic Sclerosis Workshop cont. 1025 - 1200
	Break				
	MSK Ultrasound Workshop Day 2 cont. 1300 - 1515	Immunology Workshop cont. 1315 - 1500	Bone densitometry for clinical practice 1350 - 1620	GRAPPA Workshop cont. 1245 - 1500	MRSS breakout session 1330 - 1445 NFC breakout session 1300 - 1430
	Joint injection breakout session 1330 - 1630 Vasculitis US breakout session 1330 - 1615	Break Immunology Workshop cont. 1520 - 1630		Break GRAPPA Workshop cont. 1520 - 1610	MRSS breakout session cont. 1500 - 1650 NFC breakout session cont. 1445 - 1560
	Hall 406CKD				
1700 - 1800	Opening Ceremony				
1800 - 1930	Exhibition Hall 404 - 405 Welcome Reception and Official Opening of Exhibition Hall				

Friday 23 August 2024

	Hall 406CKD	Hall 404A	Summit 2	Room 335 - 336
0800 - 0915	Rheumatoid arthritis	Rheumatology imaging - its values, development and future Coordinated by the APLAR Imaging SIG	Working together across APLAR Coordinated by the APLAR COP-COND SIG	Digital health & telemedicine Coordinated by the APLAR Digital SIG
0915 - 1045	Hall 406CKD Plenary session 1			
1045 - 1110	Break and poster viewing			
1110 - 1215	Morning symposium 1 SPONSORED BY Pfizer	Morning symposium 2 SPONSORED BY GSK	Morning symposium 3 SPONSORED BY GILEAD	Morning symposium 4 SPONSORED BY abbvie
1215 - 1330	Vasculitis	Paediatric rheumatology - kidneys, blood vessels and skin Coordinated by the APLAR Paediatric SIG	Abstract session: Inflammatory arthritis 1	Comorbidities of SLE Coordinated by the APLAR SLE SIG
1330 - 1500	Lunch symposium 1 SPONSORED BY	Lunch symposium 2 SPONSORED BY	Break and poster viewing	
1500 - 1615	Crystal arthropathy	SSc session Coordinated by the APLAR Scleroderma SIG	Abstract session: Basic science	Abstract session: Late breaking abstracts
1615 - 1645	Break and poster viewing			
1645 - 1800	Recent update in paediatric rheumatic diseases	APLAR - ACR symposium	Cancer screening in myositis Coordinated by the APLAR Myositis SIG	Rheumatoid arthritis: Challenges and opportunities Coordinated by the AYR SIG

APLAR24 Program

Saturday 24 August 2024

	Hall 406CKD	Hall 404A	Summit 2	Room 335 - 336
0800 - 0915	Reproductive health	Crystal-induced arthritis Coordinated by the APLAR Crystal-Induced Arthritis SIG	Abstract session: SLE/Lupus/vAPS	SSR-MSR special session
0915 - 1045	Hall 406CKD Plenary session 2			
1045 - 1110	Break and poster viewing			
1110 - 1215	Morning symposium 5 SPONSORED BY abbvie	Morning symposium 6 SPONSORED BY GSK	Morning symposium 7 SPONSORED BY AstraZeneca	Morning symposium 8 SPONSORED BY
1215 - 1330	SpA	Toward better management of vasculitis Coordinated by the APLAR Vasculitis SIG	Osteoarthritis Coordinated by the APLAR Osteoarthritis SIG	Unlocking the genetic mysteries of rheumatology: a journey into personalised medicine Coordinated by the APLAR Genetics SIG
1330 - 1500	Lunch symposium 3 SPONSORED BY Lilly	Break and poster viewing		
1500 - 1615	Health technologies and patient engagement	AxSpA Coordinated by the APLAR SpA SIG	Osteoporosis Coordinated by the APLAR Osteoporosis SIG	Abstract session: Myositis/Vasculitis/Pain
1615 - 1645	Break and poster viewing			
1645 - 1800	Allied health professionals	APLAR - EULAR symposium	Rheumatoid arthritis Coordinated by the APLAR RA SIG	Reproductive health Coordinated by the APLAR Reproductive SIG
1800 - 2230	Shangri-La Singapore Joint Presidential Gala Dinner			

Sunday 25 August 2024

	Hall 406CKD	Hall 404A	Summit 2	Room 335 - 336
0800 - 0915	Infections and malignancy	Abstract session: Inflammatory arthritis 2	Challenges to managing chronic musculoskeletal and rheumatic diseases Coordinated by the APLAR Social Commitment and Patient Outreach SIG	How to establish APLAR SS registry and CPG Coordinated by the APLAR Sjogren SIG
0915 - 1045	Plenary session 3: Prof Debashish Danda special lectures			
1045 - 1110	Break and poster viewing			
1110 - 1225	SLE	Osteoporosis debate	PsA	Auto-inflammatory diseases in children and adults
1225 - 1355	Lunch symposium 5 SPONSORED BY YHLO			
1355 - 1455	Year in review			
1455 - 1530	Closing Ceremony and Awards			

26th Asia-Pacific League of Associations for Rheumatology Congress
Suntec, Singapore | 21-25 August 2024

Risks of KD and MIS-C in Pediatric Patients with COVID-19 Infection: A TriNetX Based Cohort Study

Ken-Pen Weng, M.D.; Cheng-Chung James Wei, Ph.D.*

Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC

*Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC

Abstract

Background: The associations of COVID-19 with Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) remain unclear. Few large-scale studies have estimated the cumulative incidence of MIS-C and KD after COVID-19 in children.
Methods: Data were obtained from TriNetX. After propensity score matching was completed, data from 258,645 patients with COVID-19 (COVID-19 group) and 258,645 patients without COVID-19 (non-COVID-19 group) were analyzed using Cox regression. Hazard ratio (HR), 95% confidence interval (CI), and cumulative incidence of MIS-C and KD were calculated for both groups. Stratified analysis was performed to validate the results.
Results: After matching for age at baseline and sex, the risks of MIS-C and KD were higher in the COVID-19 group than in the non-COVID-19 group (HR: 3.023 [95% CI: 2.323 to 3.933] and 1.736 [95% CI: 1.273 to 2.369], respectively) (Figure 1. and Figure 2.). After matching for age at baseline, sex, race, ethnicity, and comorbidities, the risks of MIS-C and KD remained significantly higher in the COVID-19 group than in the non-COVID-19group (HR: 2.899 [95% CI: 2.173 to 3.868] and 1.435 [95% CI: 1.030 to 2.000]). When stratified by age, the risk of MIS-C was higher in the COVID-19 group—for patients aged > 5 years and ≤ 5 years (HR: 2.399 [95% CI: 1.683 to 3.418] and 2.673 [95% CI: 1.737 to 4.112], respectively)—than in the non-COVID-19 group. However, the risk of KD was elevated only in patients aged ≤ 5 years (HR: 1.808; 95% CI: 1.203 to 2.716). When stratified by COVID-19 vaccination status, the risks of MIS-C and KD were elevated in unvaccinated patients with COVID-19 (HR: 2.406 and 1.835, respectively) (Table 1.).
Conclusion: Patients with COVID-19 who are aged < 18 and ≤ 5 years have increased risks of MIS-C and KD, respectively. Further studies are required to confirm the role of COVID-19 in the pathogenesis of MIS-C and KD.

Figure 1. Kaplan–Meier curves of MIS-C between COVID-19 and non-COVID-19 groups.



Figure 2. Kaplan–Meier curves of Kawasaki disease between COVID-19 and non-COVID-19 groups.

Table 1. Subgroup analysis stratified by sex, age, race, ethnicity, infection related comorbidities, and COVID-19 vaccination.

	HRs (95% CIs)	
	MIS-C	Kawasaki disease
Sex		
Male	2.421 (1.700, 3.448)	1.662 (1.057, 2.612)
Female	3.658 (2.249, 5.950)	1.159 (0.704, 1.908)
Age (years)		
≤ 5	2.673 (1.737, 4.112)	1.808 (1.203, 2.716)
> 5	2.399 (1.683, 3.418)	1.565 (0.973, 2.520)
Race		
Black	1.687 (1.078, 2.642)	0.999 (0.469, 2.128)
White	2.938 (1.892, 4.563)	2.520 (1.511, 4.204)
Asian	-	1.549(0.259,9.272)
Other	2.202(1.405,3.453)	1.931 (1.009,3.696)
Ethnicity		
Hispanic or Latino	2.575(1.533,4.325)	2.169(1.238,3.801)
Other	2.843(2.078,3.888)	1.286(0.898,1.843)
Comorbidities		
Influenza	5.153 (1.979,13.418)	2.306(0.886,6.000)
Certain infectious and parasitic diseases	1.759(1.421,2.178)	1.201(0.909,1.588)
COVID-19 vaccination		
With	-	2.063 (0.187, 22.750)
Without	2.406 (1.878, 3.083)	1.835 (1.336, 2.522)


108


102
101


101
99


108
107